Boston, United States
Avalyn Pharma, founded in 2011 and headquartered in the United States, is pioneering advancements in the treatment of pulmonary fibrosis. With the slogan, “Revolutionizing respiratory care with every breath,” Avalyn is focused on creating innovative inhaled therapies.
The company is reshaping respiratory medicine with its approach to directly delivering treatment to the lungs, aiming to enhance efficacy and tolerability compared to traditional oral therapies. Avalyn’s promising pipeline includes two lead candidates: AP01, an optimized inhaled formulation of pirfenidone currently undergoing the Phase 2b MIST study, and AP02, a formulation of nintedanib that has completed two Phase 1 trials.
Recently, Avalyn secured a $175.00M Series C investment in September 2023, backed by prominent investors such as Novo Holdings, F-Prime Capital, Norwest Venture Partners, and others. This investment reinforces confidence in Avalyn’s mission to transform lung disease treatment with groundbreaking inhaled solutions.
Savara Inc.
